{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:28:01Z","timestamp":1773743281787,"version":"3.50.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaut.2019.102398","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T17:51:50Z","timestamp":1578505910000},"page":"102398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Treat to target in axial spondyloarthritis: From its concept to its implementation"],"prefix":"10.1016","volume":"110","author":[{"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.102398_bib1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM199306103282306","article-title":"Long-term complications of diabetes mellitus","volume":"328","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/dc06-1406","article-title":"Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register","volume":"30","author":"Eeg-Olofsson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaut.2019.102398_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M17-0939","volume":"168","author":"Qaseem","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/L18-0373","article-title":"Hemoglobin A1c targets for glycemic control with pharmacologic therapy","volume":"169","author":"Wilt","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib5","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/art.20350","article-title":"The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis","volume":"50","author":"Welsing","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib6","first-page":"361","article-title":"A proposal for modification of the New York criteria","volume":"27","author":"Van der Leiden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jbspin.2012.06.003","article-title":"Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?","volume":"79","author":"Claudepierre","year":"2012","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2019.102398_bib8","first-page":"85","article-title":"Criteria of the classification of spondylarthropathies, [in French","volume":"57","author":"Amor","year":"1991","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.jaut.2019.102398_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classificationcriteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib11","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"Smolen","year":"2011","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaut.2019.102398_bib12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landew\u00e9","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib14","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/acr.23796","article-title":"Spinal radiographic progression in early axial spondyloarthritis: five-year results from the DESIR cohort","volume":"71","author":"Ramiro","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.jaut.2019.102398_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/key128","article-title":"Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2019.102398_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13075-017-1453-3","article-title":"Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"19","author":"Protopopov M","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102398_bib17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","article-title":"Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study","volume":"75","author":"Molt\u00f3","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/acr.20364","article-title":"Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis","volume":"63","author":"Mathieu","year":"2011","journal-title":"S Arthritis Care Res"},{"issue":"5 Suppl 51","key":"10.1016\/j.jaut.2019.102398_bib19","first-page":"80","article-title":"Mortality in ankylosing spondylitis","author":"Zochling","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jbspin.2011.02.012","article-title":"Mortality in spondyloarthritis","volume":"78","author":"Claudepierre","year":"2011","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.jaut.2019.102398_bib21","article-title":"Cardiovascular disease in spondyloarthritides","author":"Papagoras","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.jaut.2019.102398_bib22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3899\/jrheum.140353","article-title":"Current smoking is associated with incident ankylosing spondylitis -- the HUNT population-based Norwegian health study","volume":"41","author":"Videm","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/ard.2008.097931","article-title":"Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence","volume":"68","author":"Marzo-Ortega","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1136\/ard.2011.152975","article-title":"HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis","volume":"70","author":"Chung","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","article-title":"Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort","volume":"71","author":"Chung","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib26","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","article-title":"Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis","volume":"68","author":"Dougados","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib27","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"J. Ann Rheum Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib28","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24024","article-title":"Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years","volume":"58","author":"AN Bennett","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib29","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1136\/annrheumdis-2017-211596","article-title":"Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001008","article-title":"ASDAS is associated with both the extent and intensity of DW-MRI spinal inflammation in active axial spondyloarthritis","volume":"5","author":"Chung","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2019.102398_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.autrev.2019.05.005","article-title":"(RA) and cardiovascular disease","volume":"18","author":"Blum","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102398_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: a comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102398_bib34","article-title":"Nonsteroidal anti-inflammatory drug use is associated with incident hypertension in ankylosing spondylitis","author":"Reveille","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2019.102398_bib35","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"J\u00fcni","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib38","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2019.102398_bib39","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"10.1016\/j.jaut.2019.102398_bib41","first-page":"30211","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication","author":"Braun","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib42","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib43","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib44","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41533-016-0004-8","article-title":"National guidelines for smoking cessation in primary care: a literature review and evidence analysis","volume":"27","author":"Verbiest","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaut.2019.102398_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib47","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3899\/jrheum.150378","article-title":"Discriminant capacity of clinical efficacy and nonsteroidal antiinflammatory drug-sparing endpoints, alone or in combination, in axial spondyloarthritis","volume":"42","author":"Dougados","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib48","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.117.027288","article-title":"Evaluating the cardiovascular safety of nonsteroidal anti-inflammatory drugs","volume":"135","author":"Antman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2019.102398_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar3786","article-title":"MRI and X-ray in axial spondyloarthritis: the relationship between inflammatory and structural changes","volume":"14","author":"Maksymowych","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102398_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with non-radiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102398_bib51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis ; Assessment of SpondyloArthritis international Society","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib54","article-title":"Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis","author":"Proft","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2019.102398_bib55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores, Assessment of SpondyloArthritis international Society","volume":"70","author":"Machado","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib57","first-page":"1","article-title":"Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts","volume":"14","author":"Gherghe","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2019.102398_bib58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2012-201610","article-title":"Psoriasis and phenotype of patients with early inflammatory back pain","volume":"72","author":"Richette","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jaut.2019.102398_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.4555","article-title":"Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis","author":"Kiltz","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12927\/hcq.2012.22845","article-title":"From discovery to design: the evolution of human factors in healthcare","volume":"15","author":"Cafazzo","year":"2012","journal-title":"Healthc. Q."},{"key":"10.1016\/j.jaut.2019.102398_bib64","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, Diabetes Control and Complications Trial Research Group","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"MA","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000311","article-title":"Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages","volume":"2","author":"Kiltz","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2019.102398_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/annrheumdis-2011-201038","article-title":"ASAS recommendations for variables to be collected in clinical trials\/epidemiological studies of spondyloarthritis","volume":"71","author":"Dougados","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib69","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis, Progress report of the ASAS Working Group, Assessments in Ankylosing Spondylitis","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib70","first-page":"851","article-title":"Evaluation of collected outcome measures in axial spondyloarthritis in daily-care rheumatology settings: the experience of the RHEVER network","volume":"33","author":"Che","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102398_bib71","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/ard.2010.146662","article-title":"Treating rheumatoid arthritis to target: the patient version of the international recommendations","volume":"70","author":"de Wit","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib72","article-title":"Impact of a nurse-led program of patient self-assessment and self-management axial spondyloarthritis :Results of a prospective, multicentre, randomized, controlled trial","author":"Molt\u00f3","year":"2018","journal-title":"EULAR"},{"key":"10.1016\/j.jaut.2019.102398_bib73","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/annrheumdis-2013-204733","article-title":"Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA)","volume":"74","author":"Dougados","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib74","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"ASASrecommendations for axial spondyloarthritis, Ann 2016 update of the","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Rheum Dis"},{"key":"10.1016\/j.jaut.2019.102398_bib75","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib76","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"HA","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib77","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"In the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib78","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib80","first-page":"626","article-title":"Lack of efficacy of rituximab in spondylarthropathies: data of 8 patients prospectively followed in the French AIR (\u2018auto-immunity and rituximab\u2019) registry","volume":"68","author":"Nocturne","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl","key":"10.1016\/j.jaut.2019.102398_bib81","first-page":"623","article-title":"Abatacept for therapy of spondyloarthritis due to therapy failure or contraindications of TNF-alpha antagonists","volume":"68","author":"Berner","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib83","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102398_bib84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib85","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib86","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2016.01.013","article-title":"Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: data from the DESIR cohort","volume":"84","author":"Molt\u00f3","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2019.102398_bib88","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/art.39208","article-title":"Gossec, brief report: nonsteroidal antiinflammatory drug-sparing effect of tumor necrosis factor inhibitors in early axial spondyloarthritis: results from the DESIR cohort","volume":"67","author":"Molt\u00f3","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib89","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib90","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102398_bib91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Karel","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102398_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum."},{"issue":"19","key":"10.1016\/j.jaut.2019.102398_bib93","first-page":"32971","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","author":"Deodhar","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib94","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"suppl 10","key":"10.1016\/j.jaut.2019.102398_bib95","article-title":"Dual neutralization of IL-17a and IL-17F with bimekizumab in patients with active ankylosing spondylitis: 48-week efficacy and safety results from a phase 2b, randomized, blinded, placebo-controlled, dose-ranging study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102398_bib96","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102398_bib97","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.102398_bib98","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119308595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119308595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:28:20Z","timestamp":1760257700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119308595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":98,"alternative-id":["S0896841119308595"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102398","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat to target in axial spondyloarthritis: From its concept to its implementation","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102398"}}